Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acurx PharmaceuticalsACXP +0.70%37 EV-to-OCF is 0.72 as of Sep. 09, 2026. GuruFocus rates ACXP with a GF Score™ of 37/100. Among 1,404 Biotechnology companies, Acurx Pharmaceuticals ranks worse than 77.07% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Acurx Pharmaceuticals's Enterprise Value is $-4.47 Mil.
Acurx Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-6.18 Mil. Therefore, Acurx Pharmaceuticals's EV-to-OCF for today is 0.72.
The historical rank and industry rank for Acurx Pharmaceuticals's EV-to-OCF or its related term are showing as below:
ACXP'
s EV-to-OCF Range Over the Past 10 Years
Min: 0.72 Med: 0 Max: 0.72
Current: 0.72
During the past 7 years, the highest EV-to-OCF of Acurx Pharmaceuticals was 0.72. The lowest was 0.72. And the median was .
ACXP's EV-to-OCF is ranked worse than 77.07% of 1404
companies
in the Biotechnology industry
Industry Median: -3.65
vs ACXP: 0.72
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Acurx Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Acurx Pharmaceuticals's share price for today is $1.44.
Acurx Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.690.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Acurx Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acurx Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Acurx Pharmaceuticals's EV-to-OCF falls into.
Acurx Pharmaceuticals's current Enterprise Value is $-4.47 Mil.
Acurx Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acurx Pharmaceuticals (ACXP) has a EV-to-OCF of 0.72 as of Sep. 09, 2026. Over the past decade, Acurx Pharmaceuticals' EV-to-OCF has ranged from 0.72 to 0.72. According to the industry distribution chart, Acurx Pharmaceuticals ranks #1082 out of 1404 companies in the Biotechnology industry, placing it in the top 77.1%.
Is Acurx Pharmaceuticals' EV-to-OCF too high?
Acurx Pharmaceuticals' current EV-to-OCF is 0.72. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 0.72. Based on the distribution chart, Acurx Pharmaceuticals ranks #1082 out of 1404 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Acurx Pharmaceuticals has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Acurx Pharmaceuticals' EV-to-OCF compare to ENVB and HCWB?
According to the Biotechnology industry distribution chart, Acurx Pharmaceuticals ranks #1082 out of 1404 companies for EV-to-OCF. This places Acurx Pharmaceuticals in the lower half of its industry. Historically, Acurx Pharmaceuticals' own EV-to-OCF has ranged from 0.72 to 0.72 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Acurx Pharmaceuticals's current EV-to-OCF is 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acurx Pharmaceuticals stock overvalued right now?
Acurx Pharmaceuticals (ACXP) has a current EV-to-OCF of 0.72. The current EV-to-OCF is 0.72. Acurx Pharmaceuticals' overall GF Score™ is 37/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Acurx Pharmaceuticals (ACXP), the current EV-to-OCF is 0.72 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
37GF Score
Get the complete analysis for ACXP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACXP has been successfully added to your 
